IIUM Repository

Long term efficacy and persistence of biologics therapy in Crohn’s disease in multiracial Asian country

Xin Hui, Khoo and Nik Muhamad Affendi, Nik Arsyad and Leow, Alex Hwong Ruey and Hilmi, Ida Normiha (2023) Long term efficacy and persistence of biologics therapy in Crohn’s disease in multiracial Asian country. Journal of Gastroenterology and Hepatology, 38 (S3). p. 271. ISSN 0815-9319 E-ISSN 1440-1746

[img] PDF - Published Version
Restricted to Repository staff only

Download (609kB) | Request a copy

Abstract

Background and Aim:Biologic therapy is an effective treatment inmoderate-to-severe Crohn disease (CD); however, there is a lack of head-to-head study to the compare efficacy between available biologic therapy.We sought to determine efficacy and persistence of the currently availabletherapy in biologic naïve CD patients in our center. Methods:A retrospective, single-center study was conducted where all bi-ologic naïve CD patients who were started on biologics therapy were re-cruited. Demographic and baseline clinical characteristic data wascollected. Clinical remission and persistence up to 3 years after startingtreatment were analyzed. Results:A total of 118 patients were recruited into this study. Mean agewas 30.6 ± 10.9 year old. 61% (n= 72) were male and 39% (n= 46) werefemale. Ethnicity, Indian 44.9% (n= 53), Chinese 34.7% (n= 41) and Ma-lay 19.5% (n= 23). Mean disease duration was 7.57 ± 5.1 years. Locationof disease was as follows; 34.7% (n= 41) Ileal, 28.8% (n= 34) colon,32.2% (n= 38) ileocolon and 4.2% (n= 5) isolated upper GI. Majorityhad non-penetrating non-stricturing disease 70.3% (n= 83) followed by17.8% (n= 21) stricturing disease and 11.9% (n= 14) penetrating disease.27.1% (n= 32) had perianal disease. The median duration of biologic ther-apy was 26.5 ± 26.8 months. Clinical remission and persistence of biologictherapy are shown in Figure 1. Conclusion:In this study, infliximab and ustekinumab have significantlyhigher efficacy and persistence as compared to adalimumab andvedolizumab although this data has to be interpreted with caution due tothe unequal number of patients in each group and retrospective nature ofstudy.

Item Type: Article (other)
Subjects: R Medicine > R Medicine (General)
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button): Kulliyyah of Medicine
Depositing User: Dr Nik Arsyad Nik Muhamad Affendi
Date Deposited: 16 Jan 2024 10:07
Last Modified: 16 Jan 2024 10:07
URI: http://irep.iium.edu.my/id/eprint/110173

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year